Xilio Therapeutics Faces Delisting Concerns
Ticker: XLO · Form: 8-K · Filed: Aug 28, 2025 · CIK: 1840233
Sentiment: bearish
Topics: delisting, listing-rule-violation, regulatory-filing
Related Tickers: XLO
TL;DR
Xilio's stock is at risk of being delisted.
AI Summary
Xilio Therapeutics, Inc. filed an 8-K on August 28, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The earliest event reported was on August 22, 2025. The company is incorporated in Delaware and its principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts.
Why It Matters
This filing indicates potential delisting from a stock exchange, which could significantly impact the liquidity and valuation of Xilio Therapeutics' stock.
Risk Assessment
Risk Level: high — The filing explicitly states a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard,' indicating a significant risk to the company's exchange listing.
Key Players & Entities
- Xilio Therapeutics, Inc. (company) — Registrant
- August 22, 2025 (date) — Earliest event reported
- August 28, 2025 (date) — Filing date
- 828 Winter Street, Suite 300, Waltham, Massachusetts (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has Xilio Therapeutics failed to satisfy?
The filing does not specify the exact rule or standard that Xilio Therapeutics has failed to satisfy, only that a notice has been issued.
What is the earliest date associated with the delisting notice?
The earliest event reported in relation to this notice was on August 22, 2025.
Where are Xilio Therapeutics' principal executive offices located?
Xilio Therapeutics' principal executive offices are located at 828 Winter Street, Suite 300, Waltham, Massachusetts.
What is the company's Central Index Key (CIK)?
Xilio Therapeutics, Inc.'s Central Index Key is 0001840233.
What is the SEC file number for Xilio Therapeutics?
The SEC file number for Xilio Therapeutics is 001-40925.
Filing Stats: 771 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2025-08-28 16:05:23
Key Financial Figures
- $0.0001 — ich registered Common stock, par value $0.0001 per share XLO Nasdaq Global Select
- $10.0 million — he requirement to maintain a minimum of $10.0 million in stockholders' equity, as required by
- $7,069,000 — ompany reported stockholders' equity of $7,069,000 in its Quarterly Report on Form 10-Q fo
- $1.00 m — f the Company's failure to maintain the $1.00 minimum bid price required for continued
Filing Documents
- xlo-20250822x8k.htm (8-K) — 44KB
- 0001558370-25-011802.txt ( ) — 158KB
- xlo-20250822.xsd (EX-101.SCH) — 3KB
- xlo-20250822_lab.xml (EX-101.LAB) — 16KB
- xlo-20250822_pre.xml (EX-101.PRE) — 10KB
- xlo-20250822x8k_htm.xml (XML) — 5KB
01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On August 22, 2025, Xilio Therapeutics, Inc. (the "Company") received a deficiency letter (the "Letter") from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market, LLC ("Nasdaq") notifying the Company that it is not in compliance with the requirement to maintain a minimum of $10.0 million in stockholders' equity, as required by Nasdaq Listing Rule 5450(b)(1)(A) for continued listing on The Nasdaq Global Select Market. As stated in the Letter, the Company reported stockholders' equity of $7,069,000 in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025. The Letter has no immediate effect on the listing of the Company's common stock. In accordance with Nasdaq Listing Rule 5810(c)(2)(C), the Company has 45 calendar days (or until October 6, 2025) to submit a plan to regain compliance with the stockholders' equity requirement. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the Letter to evidence compliance. Alternatively, the Company may apply to transfer the Company's securities to The Nasdaq Capital Market, provided that it meets the requirements for continued listing on The Nasdaq Capital Market. As previously disclosed in a Current Report on Form 8-K filed on April 8, 2025 , the Company received a deficiency letter from the Staff of Nasdaq on April 4, 2025, notifying it of the Company's failure to maintain the $1.00 minimum bid price required for continued listing on The Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company's initial period of 180 calendar days to regain compliance with the Minimum Bid Requirement expires on October 1, 2025, after which it may be eligible for an additional 180 calendar day compliance period if it transfers its secur
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. XILIO THERAPEUTICS, INC. Date: August 28, 2025 By: /s/ Caroline Hensley Caroline Hensley Chief Legal Officer